14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ICCC vs IG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Principal Investment Grade Corporate Active ETF (IG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas IG carries 45.4/100 (HOLD) at $19.61 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While IG currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (15.2% vs. N/A operating margin) and revenue trajectory (+11.5% vs. N/A YoY).
Technical & Structure Timing Caution: ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5); meanwhile IG is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 39.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICCC vs IG. Trailing 12-month operating profitability (ICCC 15.2% vs IG N/A) and valuation multiples (ICCC N/M vs IG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ICCC vs IG Key Questions & Quantitative Answers
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Principal Investment Grade Corporate Active ETF (IG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas IG carries 45.4/100 (HOLD) at $19.61 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While IG currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (15.2% vs. N/A operating margin) and revenue trajectory (+11.5% vs. N/A YoY). Technical & Structure Timing Caution: ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5); meanwhile IG is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 39.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ICCC leads the Growth & Scale pillar: ICCC posts +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin), compared with IG at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ICCC generates $67M in USD-normalized revenue versus N/A for IG. In operating R&D and SG&A reinvestment, ICCC deploys 25.1% of Rev ($17M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IG.
ICCC screens cheaper on headline valuation multiples. ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin), whereas IG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICCC (2.6% ROE) versus IG (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk). By comparison, IG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 7% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.